bjsports-2015-095343

PLA2G3 Antibody Summary

    Immunogen
    Synthetic 16 amino acid peptide from internal region of human PLA2G3.
    Epitope
    internal domain of human
    Specificity
    Human PLA2G3. BLAST analysis of the peptide immunogen showed no homology with other human proteins.
    Predicted Species
    Mouse (94%), Rat (94%), Hamster (94%), Canine (94%), Primate (94%), Monkey (100%). Backed by our 100% Guarantee.
    Isotype
    IgG
    Clonality
    Polyclonal
    Host
    Rabbit
    Gene
    PLA2G3
    Purity
    Immunogen affinity purified
    Innovators Reward
    Test in a species/application not listed above to receive a full credit towards a future purchase.

    Learn about the Innovators Reward

Applications/Dilutions

    Dilutions
        Immunohistochemistry-Paraffin 10 ug/ml
    Positive Control PLA2G3 Lysate (NBL1-14473)

Reactivity Notes

Predicted cross-reactivity based on sequence identity: Gorilla (100%), Gibbon (100%), Marmoset (94%), Elephant (88%), Panda (88%), Rabbit (88%), Bovine (81%), Equine (81%), Porcine (81%).

Packaging, Storage & Formulations

    Storage
    Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
    Buffer
    PBS
    Preservative
    0.1% Sodium Azide
    Concentration
    1 mg/ml
    Purity
    Immunogen affinity purified

Alternate Names for PLA2G3 Antibody

      EC 3.1.1.4
      GIII sPLA2
      GIII-SPLA2
      group 3 secretory phospholipase A2
      group III secreted phospholipase A2
      Group III secretory phospholipase A2
      Phosphatidylcholine 2-acylhydrolase 3
      phosphatidylcholine 2-acylhydrolase GIII
      phospholipase A2, group III
      SPLA2III
      sPLA2-III

Background

PLA2G3 (Human group III secreted phospholipase A2) belongs to a superfamily of intracellular and secreted enzymes that catalyze the hydrolysis of glycerophospholipids to release fatty acids and lysophospholipids. Human PLA2G3 has been shown to be a calcium dependent enzyme, consisting of a central group III sPLA2 domain flanked by unique N and C terminal domains that are proteolytically cleavedin most tissues. The sPLA2 domain is sufficient for catalytic activity. SPLA2-III is expressed in the microvascular endothelium of tissues with inflammation, ischemic injury and cancer.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

PF-670463

Related Post